Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ischemic Heart Disease

  Free Subscription

Articles published in
J Cardiovasc Pharmacol
    February 2024
  1. CATURANO A, Nilo D, Russo V, Galiero R, et al
    Assessment of the Effectiveness of Ticagrelor Preloading in Mitigating Periprocedural Myocardial Injury among Non-ST Elevation Myocardial Infarction Patients Opting for an Early Invasive Approach.
    J Cardiovasc Pharmacol. 2024 Feb 5. doi: 10.1097/FJC.0000000000001548.
    >> Share

    January 2024
  2. KARACA OF, Cimci M, Raimoglou D, Durmaz E, et al
    Impact of preloading strategy with ticagrelor on periprocedural myocardial injury in patients with non-ST elevation myocardial infarction undergoing early invasive strategy.
    J Cardiovasc Pharmacol. 2024 Jan 15. doi: 10.1097/FJC.0000000000001540.
    >> Share

  3. BELTRAN-ORNELAS JH, Silva-Velasco DL, Tapia-Martinez J, Sanchez-Lopez A, et al
    NaHS reverts chronic stress-induced cardiovascular alterations by reducing oxidative stress.
    J Cardiovasc Pharmacol. 2024 Jan 11. doi: 10.1097/FJC.0000000000001538.
    >> Share

  4. LI X, Yu T, Jiang Q, Tan J, et al
    The efficacy of traditional Chinese herbal medicine across multiple cardiovascular diseases: an umbrella review of systematic reviews of randomized controlled trials.
    J Cardiovasc Pharmacol. 2024 Jan 9. doi: 10.1097/FJC.0000000000001535.
    >> Share

  5. TZENG WS, Klein CF, Roth RH, Cho Y, et al
    Central Sleep Apnea in Patients With Coronary Heart Disease Taking P2Y12 Inhibitors.
    J Cardiovasc Pharmacol. 2024;83:126-130.
    >> Share

  6. ZHU Y, He YJ, Yu Y, Xu D, et al
    Aldehyde Dehydrogenase 2 Preserves Mitochondrial Function in the Ischemic Heart: A Redox-dependent Mechanism for AMPK Activation by Thioredoxin-1.
    J Cardiovasc Pharmacol. 2024;83:93-104.
    >> Share

    December 2023
  7. SPADAFORA L, Gaudio C, Biondi-Zoccai G, Frati G, et al
    Catalysts of cardiovascular electromechanical harmony? Unveiling the impact of RAS Inhibitors and ARNI on atrial fibrillation recurrence after ablation.
    J Cardiovasc Pharmacol. 2023 Dec 27. doi: 10.1097/FJC.0000000000001537.
    >> Share

  8. BOOZ GW
    Journal of Cardiovascular Pharmacology Welcomes New Associates.
    J Cardiovasc Pharmacol. 2023 Dec 13. doi: 10.1097/FJC.0000000000001522.
    >> Share

  9. KREUTZ RP, Leon IG, Bain ER, George B, et al
    Heparin Dosing During Percutaneous Coronary Intervention and Obesity.
    J Cardiovasc Pharmacol. 2023 Dec 12. doi: 10.1097/FJC.0000000000001525.
    >> Share

    November 2023
  10. LI D, Li L, Dong S, Yu Y, et al
    ALKBH5 regulates N(6)-methyladenosine (m6A) methylation of MG53 to attenuate myocardial infarction by inhibiting apoptosis and oxidative stress.
    J Cardiovasc Pharmacol. 2023 Nov 17. doi: 10.1097/FJC.0000000000001515.
    >> Share

  11. APOSTOLOS A, Travlos C, Tsioulos G, Chlorogiannis DD, et al
    Duration Of Dual Antiplatelet Treatment After Percutaneous Coronary Intervention In Patients With Diabetes: A Systematic Review And Meta-Analysis.
    J Cardiovasc Pharmacol. 2023 Nov 7. doi: 10.1097/FJC.0000000000001503.
    >> Share

  12. YU M, Zhu ZF, Yang F, Yuan YF, et al
    Different anti-inflammatory drugs on high-sensitivity C-reactive protein in patients after percutaneous coronary intervention: A pilot randomized clinical trial.
    J Cardiovasc Pharmacol. 2023 Nov 7. doi: 10.1097/FJC.0000000000001509.
    >> Share

  13. KELLY MS, Dacey A, Siana A, Ojeda J, et al
    Efficacy and Safety of a polypill to reduce cardiovascular events: A review of clinical trials.
    J Cardiovasc Pharmacol. 2023 Nov 4. doi: 10.1097/FJC.0000000000001508.
    >> Share

  14. LI Y, Lin H, Tang H, Zhu K, et al
    The STING-IRF3 Signaling Pathway, Mediated by Endoplasmic Reticulum Stress, Contributes to Impaired Myocardial Autophagic Flux After Ischemia/Reperfusion.
    J Cardiovasc Pharmacol. 2023;82:389-399.
    >> Share

    October 2023
  15. GAO D, Hu L, Lv H, Lian L, et al
    Ferroptosis Involved in Cardiovascular Diseases: Mechanism Exploration of Ferroptosis' Role in Common Pathological Changes.
    J Cardiovasc Pharmacol. 2023 Oct 27. doi: 10.1097/FJC.0000000000001507.
    >> Share

  16. PRESUME J, Gomes DA, Ferreira J, Albuquerque F, et al
    Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2023;82:298-307.
    >> Share

    September 2023
  17. BUONPANE A, Biondi-Zoccai G, Versaci F
    Molecular insights on ischemic heart failure: from core genes to hearts.
    J Cardiovasc Pharmacol. 2023 Sep 26. doi: 10.1097/FJC.0000000000001486.
    >> Share

  18. LIN L, Zicheng L, Shaohua G
    Post-acute myocardial infarction heart failure core genes and relevant signaling pathways.
    J Cardiovasc Pharmacol. 2023 Sep 6. doi: 10.1097/FJC.0000000000001481.
    >> Share

  19. QIN H, Zhou J
    Myocardial Protection by Desflurane: From Basic Mechanisms to Clinical Applications.
    J Cardiovasc Pharmacol. 2023;82:169-179.
    >> Share

    August 2023
  20. SHAH JT, Shah KT, Femia AN, Lo Sicco KI, et al
    Cardiovascular Risk Management in Patients Treated with JAK Inhibitors.
    J Cardiovasc Pharmacol. 2023 Aug 10. doi: 10.1097/FJC.0000000000001470.
    >> Share

  21. KAPLAN A, Lakkis B, El-Samadi L, Karaayvaz EB, et al
    Cooling Down Inflammation in the Cardiovascular System via the Nicotinic Acetylcholine Receptor.
    J Cardiovasc Pharmacol. 2023 Aug 4. doi: 10.1097/FJC.0000000000001455.
    >> Share

  22. CHEN R, Zhang Y, Zhou H, Hu Y, et al
    SGLT2 inhibitor-pretreated macrophage transplantation improves adverse ventricular remodeling after acute myocardial infarction.
    J Cardiovasc Pharmacol. 2023 Aug 3. doi: 10.1097/FJC.0000000000001466.
    >> Share

  23. MORONI F, Abbate A
    Anti-inflammatory (colchicine) treatment for secondary prevention in coronary artery disease: a milestone has been met.
    J Cardiovasc Pharmacol. 2023 Aug 3. doi: 10.1097/FJC.0000000000001467.
    >> Share

  24. ALGAIDI SH, Alghamdi DI, Algheffari SG, Alzahrani RA, et al
    Long-term cardiovascular adverse events induced by fluoroquinolones: A retrospective case-control study.
    J Cardiovasc Pharmacol. 2023 Aug 1. doi: 10.1097/FJC.0000000000001459.
    >> Share

  25. BORGI M, Peruzzi M, Biondi-Zoccai G, Versaci F, et al
    Trimetazidine after coronary revascularization: much ado about nothing?
    J Cardiovasc Pharmacol. 2023 Aug 1. doi: 10.1097/FJC.0000000000001462.
    >> Share

  26. TIAN MY, Wang XY, Chen F, Guo YF, et al
    Comparison of Ticagrelor Monotherapy and Ticagrelor plus Aspirin Among Patients with Acute Coronary Syndrome Combined with High-Risk of Gastrointestinal Bleeding after PCI: a Retrospective Cohort Study.
    J Cardiovasc Pharmacol. 2023 Aug 1. doi: 10.1097/FJC.0000000000001461.
    >> Share

  27. TOPRAK K, Kaplangoray M, Memioglu T, Inanir M, et al
    The Relationship Between Nitrate-Induced Headache and -Blood Viscosity: An Observational Prospective Study.
    J Cardiovasc Pharmacol. 2023;82:162-168.
    >> Share

  28. WANG CC, Zhao Q, Guo BY, Hao J, et al
    The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study.
    J Cardiovasc Pharmacol. 2023;82:148-156.
    >> Share

  29. GOEL H, Carey M, Elshaikh A, Krinock M, et al
    Cardioprotective and Antianginal Efficacy of Nicorandil: A Comprehensive Review.
    J Cardiovasc Pharmacol. 2023;82:69-85.
    >> Share

  30. XIAO Z, Guan L, Shi H, Yu Y, et al
    Trimetazidine Affects Mitochondrial Calcium Uniporter Expression to Restore Ischemic Heart Function via Reactive Oxygen Species/NFkappaB Pathway Inhibition.
    J Cardiovasc Pharmacol. 2023;82:104-116.
    >> Share

  31. LI W, Luo Y, Huang Z, Shen S, et al
    Costunolide Protects Myocardium From Ischemia Reperfusion Injury by Inhibiting Oxidative Stress Through Nrf2/Keap1 Pathway Activation.
    J Cardiovasc Pharmacol. 2023;82:117-127.
    >> Share

    July 2023
  32. LI Y, Zhang J, He J, Chen X, et al
    Association of the L3MBTL3 rs1125970 and rs4897367 gene polymorphisms with coronary heart disease susceptibility in the Chinese population: a case-control study.
    J Cardiovasc Pharmacol. 2023 Jul 31. doi: 10.1097/FJC.0000000000001464.
    >> Share

  33. WHITE RT, Sirek ME, Marrs JC
    Oral Oncolytics and Cardiovascular Risk Management and Monitoring.
    J Cardiovasc Pharmacol. 2023 Jul 27. doi: 10.1097/FJC.0000000000001458.
    >> Share

  34. PARK S, Chang J, Hong SP, Jin ES, et al
    Impact of Trimetazidine on the Incident Heart Failure Following Coronary Artery Revascularization.
    J Cardiovasc Pharmacol. 2023 Jul 11. doi: 10.1097/FJC.0000000000001453.
    >> Share

  35. KIM HY, Mok J, Kim JY, Jeon D, et al
    Effect of Angiotensin Receptor Blocker Dose in Myocardial Infarction With Preserved Left Ventricular Systolic Function.
    J Cardiovasc Pharmacol. 2023;82:52-60.
    >> Share

    May 2023
  36. FU C, Yu S, Liu Z, Wang J, et al
    PFKFB2 inhibits ferroptosis in myocardial ischemia/reperfusion injury through AMPK activation.
    J Cardiovasc Pharmacol. 2023 May 5. doi: 10.1097/FJC.0000000000001437.
    >> Share

  37. HASSAN AE, Hadhoud S, Elmahdi E, Elkattawy HA, et al
    Potential Cardioprotective Role of Menaquinone-4 Against Cardiac Ischemia-reperfusion Injury.
    J Cardiovasc Pharmacol. 2023;81:381-388.
    >> Share

    April 2023
  38. WANG S, Mu Y, Tan L, Hao J, et al
    Efficacy and safety of different dosing regimens of colchicine in patients with coronary artery disease: a network meta-analysis of 15 randomized controlled trials.
    J Cardiovasc Pharmacol. 2023 Apr 6. doi: 10.1097/FJC.0000000000001426.
    >> Share

    March 2023
  39. SPADAFORA L, Crimi G, Porto I, Biondi-Zoccai G, et al
    Statin therapy after myocardial infarction in patients with renal failure: the longer, the merrier!
    J Cardiovasc Pharmacol. 2023 Mar 16. doi: 10.1097/FJC.0000000000001420.
    >> Share

  40. ZHANG D, Mi Z, Peng J, Yang T, et al
    Non-alcoholic fatty liver disease as an emerging risk factor and potential intervention target for atherosclerotic cardiovascular diseases.
    J Cardiovasc Pharmacol. 2023 Mar 13. doi: 10.1097/FJC.0000000000001418.
    >> Share

  41. KUANG N, Shu B, Yang F, Li S, et al
    TRAIL or TRAIL-R2 as a predictive biomarker for mortality or cardiovascular events: A systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2023 Mar 9. doi: 10.1097/FJC.0000000000001415.
    >> Share

    February 2023
  42. LACOURSIERE L, Woodruff AE, Mills K, Chilbert MR, et al
    A Retrospective Review of Cardiogenic Shock Development in Patients with ST-elevation Myocardial Infarction (STEMI) and Percutaneous Coronary Intervention (PCI) Receiving Early Beta-Blockers.
    J Cardiovasc Pharmacol. 2023 Feb 23. doi: 10.1097/FJC.0000000000001412.
    >> Share

  43. ROSTAMZADEH F, Jafarinejad-Farsangi S, Ansari-Asl Z, Farrokhi MS, et al
    Treatment for myocardial infarction: in vivo evaluation of curcumin-loaded PEGylated-GQDs nanoparticles.
    J Cardiovasc Pharmacol. 2023 Feb 23. doi: 10.1097/FJC.0000000000001410.
    >> Share

  44. MORONI F, Ayers MP, Dixon DL, Abbate A, et al
    PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 INHIBITORS (PCSK9i) IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: REAL-WORLD DATA WELCOME.
    J Cardiovasc Pharmacol. 2023 Feb 23. doi: 10.1097/FJC.0000000000001411.
    >> Share

  45. CORCIONE N, Biondi-Zoccai G, Castellani V, Carnevale R, et al
    Vitamin D3 and omega-3 fatty acids: A new approach for cardiovascular prevention.
    J Cardiovasc Pharmacol. 2023 Feb 15. doi: 10.1097/FJC.0000000000001407.
    >> Share

  46. KHEDRI M, Szummer K, Lundman P, Jernberg T, et al
    Statin treatment intensity, discontinuation and long-term outcome in patients with acute myocardial infarction and impaired kidney function.
    J Cardiovasc Pharmacol. 2023 Feb 1. doi: 10.1097/FJC.0000000000001402.
    >> Share

  47. RUSSO V, Fabiani D, Leonardi S, Attena E, et al
    Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis.
    J Cardiovasc Pharmacol. 2023;81:129-133.
    >> Share

    December 2022
  48. PENG W, Zhang Y, Lin B, Lin Y, et al
    Clinical outcomes of individualized antiplatelet therapy based on platelet function test in patients after percutaneous coronary intervention: a systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Dec 21. doi: 10.1097/FJC.0000000000001393.
    >> Share

    November 2022
  49. PENG W, Zhang Y, Li X, Lin Y, et al
    Efficacy and safety of clopidogrel versus ticagrelor for stabilized patients with acute coronary syndromes after percutaneous coronary intervention: results from a real-world registry in China.
    J Cardiovasc Pharmacol. 2022 Nov 18. doi: 10.1097/FJC.0000000000001381.
    >> Share

  50. ALEXOPOULOS D, Dragona VM, Varlamos C, Ktenas D, et al
    One-year outcomes in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the Greek Antiplatelet Atrial Fibrillation (GRAPE-AF) registry.
    J Cardiovasc Pharmacol. 2022 Nov 18. doi: 10.1097/FJC.0000000000001389.
    >> Share

  51. ZHANG H, Jing L, Zhai C, Xiang Q, et al
    The Intestinal Flora Metabolite Trimethylamine Oxide Is Inextricably Linked to Coronary Heart Disease.
    J Cardiovasc Pharmacol. 2022 Nov 18. doi: 10.1097/FJC.0000000000001387.
    >> Share

    October 2022
  52. DEO S, Ueda P, Sheikh MA, Altarabsheh S, et al
    Lipid-lowering in 'very high risk' patients undergoing coronary artery bypass surgery and its projected reduction in risk for recurrent vascular events: A Monte Carlo stepwise simulation approach.
    J Cardiovasc Pharmacol. 2022 Oct 12. pii: 00005344-990000000-00121.
    >> Share

  53. SEIJAS-AMIGO J, Cordero A, Fernandez Del Olmo R, Cortez Quiroga GA, et al
    Patients with high cardiovascular risk as candidates to bempedoic acid after treatment with statins, ezetimibe and PCSK9 inhibitors. An estimation and cost-effectiveness analysis.
    J Cardiovasc Pharmacol. 2022 Oct 11. pii: 00005344-990000000-00111.
    >> Share

  54. GIORDANO S, Spadafora L, Biondi-Zoccai G, Bernardi M, et al
    Magnitude of low-density lipoprotein reduction and impact on major cardiovascular outcomes.
    J Cardiovasc Pharmacol. 2022 Oct 10. pii: 00005344-990000000-00119.
    >> Share

  55. LA VECCHIA G, Del Buono MG
    Colchicine in Patients With STEMI: More Doubts Than Certainties.
    J Cardiovasc Pharmacol. 2022;80:499.
    >> Share

    September 2022
  56. MASTER YW, Master QZ, Master HC, Master ZW, et al
    Effects of recombinant human brain natriuretic peptide on atrial fibrillation after coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2022 Sep 9. pii: 00005344-990000000-00114.
    >> Share

  57. JI M, Li Y, Liu Y, Ma G, et al
    Vaspin Ameliorates Cardiac Remodeling by Suppressing Phosphoinositide 3-Kinase/Protein Kinase B Pathway to Improve Oxidative Stress in Heart Failure Rats.
    J Cardiovasc Pharmacol. 2022;80:442-452.
    >> Share

  58. CHEN JY, Li T, Wang JL, Wang ZL, et al
    Protective Effects and Mechanisms of Melatonin on Stress Myocardial Injury in Rats.
    J Cardiovasc Pharmacol. 2022;80:417-429.
    >> Share

    August 2022
  59. ENNEZAT PV, Guerbaai RA, Marechaux S, Le Jemtel TH, et al
    Extent of LDL-cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: a Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00106.
    >> Share

  60. YANG S, Shen W, Zhang HZ, Wang CX, et al
    Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00107.
    >> Share

  61. AMIN G, Massoud G, Fares S, Booz GW, et al
    Colchicine and acute coronary syndromes: a new trick for an old drug?
    J Cardiovasc Pharmacol. 2022 Aug 18. pii: 00005344-990000000-00100.
    >> Share

  62. HUI J, Bai T, Liang L, He Q, et al
    Efficacy and Safety of Shortened Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022 Aug 15. pii: 00005344-990000000-00094.
    >> Share

  63. BURASHNIKOV A, Abbate A, Booz GW
    Cardiovascular complications of anti-cancer therapy: a developing storm in medicine.
    J Cardiovasc Pharmacol. 2022 Aug 15. pii: 00005344-990000000-00095.
    >> Share

  64. ANTO S, Sathish V, Sun C, O'Rourke ST, et al
    Apelin-Induced Relaxation of Coronary Arteries is Impaired in a Model of Second-Hand Cigarette Smoke Exposure.
    J Cardiovasc Pharmacol. 2022 Aug 11. pii: 00005344-990000000-00093.
    >> Share

  65. CALCAGNO S, Corcione N, Biondi-Zoccai G, Giordano A, et al
    De-Escalation of Dual Antiplatelet Therapy: Will We Ever Get to the Right Method?
    J Cardiovasc Pharmacol. 2022;80:203-205.
    >> Share

    July 2022
  66. PEPE M, Napoli G, Biondi-Zoccai G, Giordano A, et al
    Anti-inflammatory therapy for acute coronary syndromes: is it time for a shift in the treatment paradigm?
    J Cardiovasc Pharmacol. 2022 Jul 20. pii: 00005344-990000000-00085.
    >> Share

  67. SHARMA P, Sharma N
    Advances in Nano-formulated Polyphenols for Protection against Cardiovascular diseases.
    J Cardiovasc Pharmacol. 2022 Jul 18. pii: 00005344-990000000-00082.
    >> Share

  68. VAN TASSELL BW, Wohlford GF, Del Buono MG, Damonte JI, et al
    Safety, tolerability and effects of a single subcutaneous administration of SP16-a SERPIN-like, small peptide agonist of the Low-Density Lipoprotein-like Receptor 1 -on the acute inflammatory response in patients with ST-segment elevation Myocardial I
    J Cardiovasc Pharmacol. 2022 Jul 12. pii: 00005344-990000000-00079.
    >> Share

  69. YANG G, Gai X, Han M, Gao F, et al
    Aberrant circulating SNHG1 serves as a biomarker to distinguish acute myocardial infarction and construction of a risk model for secondary heart failure.
    J Cardiovasc Pharmacol. 2022 Jul 11. pii: 00005344-990000000-00043.
    >> Share

  70. AKANDE O, Chen Q, Cholyway R, Toldo S, et al
    Modulation of Mitochondrial Respiration During Early Reperfusion Reduces Cardiac Injury in Donation After Circulatory Death Hearts.
    J Cardiovasc Pharmacol. 2022;80:148-157.
    >> Share

    June 2022
  71. HOSSEINI SH, Talasaz AH, Alidoosti M, Tajdini M, et al
    Pre-Procedural Colchicine in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: a Randomized Controlled Trial (PodCAST-PCI).
    J Cardiovasc Pharmacol. 2022 Jun 22. pii: 00005344-990000000-00067.
    >> Share

  72. BAO YL, Gu LF, Du C, Wang YX, et al
    Evaluating the utility of colchicine in acute coronary syndrome: A systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jun 22. pii: 00005344-990000000-00068.
    >> Share

    May 2022
  73. SOTHIVELR V, Hasan MY, Saffian SM, Zainalabidin S, et al
    Revisiting miRNA-21 as a Therapeutic Strategy for Myocardial Infarction: A Systematic Review.
    J Cardiovasc Pharmacol. 2022 May 20. pii: 00005344-990000000-00055.
    >> Share

  74. LYCOURAS MM, Clark CM, Mills K, Gupta A, et al
    Early versus late administration of P2Y12 inhibitors in non-ST segment elevation myocardial infarction and delayed cardiac catherization.
    J Cardiovasc Pharmacol. 2022 May 13. pii: 00005344-990000000-00051.
    >> Share

  75. ZHONG PY, Shang YS, Bai N, Ma Y, et al
    Dual antiplatelet therapy after drug-eluting stents implantation in East Asians: a network meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2022 May 6. pii: 00005344-990000000-00042.
    >> Share

  76. SHANG YS, Zhong PY, Ma Y, Bai N, et al
    Efficacy and Safety of Proton Pump Inhibitors in Patients with Coronary Artery Diseases Receiving Oral Antiplatelet Agents and/or Anticoagulants: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2022 May 4. pii: 00005344-990000000-00036.
    >> Share

  77. XUE K, Chen S, Chai J, Yan W, et al
    Upregulation of Periostin Through CREB Participates in Myocardial Infarction-induced Myocardial Fibrosis.
    J Cardiovasc Pharmacol. 2022;79:687-697.
    >> Share

    April 2022
  78. DENNY O, Woodruff AE, Mills K, Chilbert MR, et al
    Comparison of ischemic and bleeding events between short versus long duration tirofiban regimens in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    J Cardiovasc Pharmacol. 2022 Apr 29. pii: 00005344-990000000-00037.
    >> Share

  79. GITTO M, Kotinas AS, Terzi R, Oliva A, et al
    Biochemical efficacy of sodium-glucose cotransporter 2 inhibitors by cardiovascular risk profile and volume status in a real-world diabetic population.
    J Cardiovasc Pharmacol. 2022 Apr 14. pii: 00005344-990000000-00025.
    >> Share

  80. SHAN C, Degryse B, Tolan P, Custaud MA, et al
    Pleiotropic effects of Icariside II on the cardiovascular system: Novel applications of ethnopharmacology in targeting vascular remodelling.
    J Cardiovasc Pharmacol. 2022 Apr 12. pii: 00005344-990000000-00024.
    >> Share

  81. BAI N, Ma Y, Niu Y, Zhong PY, et al
    Efficacy and safety of de-escalation of antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized clinical trials.
    J Cardiovasc Pharmacol. 2022 Apr 8. pii: 00005344-990000000-00022.
    >> Share

  82. ADEVA-ANDANY MM, Fernandez-Fernandez C, Carneiro-Freire N, Castro-Quintela E, et al
    Cardiovascular protection associated with cilostazol, colchicine and target of rapamycin inhibitors.
    J Cardiovasc Pharmacol. 2022 Apr 6. pii: 00005344-990000000-00019.
    >> Share

  83. DAI H, Zhao N, Zheng Y
    CircLDLR modulates the proliferation and apoptosis of vascular smooth muscle cells in coronary artery disease through miR-26-5p/KDM6A axis.
    J Cardiovasc Pharmacol. 2022 Apr 6. pii: 00005344-990000000-00018.
    >> Share

  84. AKYILDIZ AG, Biondi-Zoccai G, De Biase D
    Impact of the Gastrointestinal Tract Microbiota on Cardiovascular Health and Pathophysiology.
    J Cardiovasc Pharmacol. 2022 Apr 6. pii: 00005344-990000000-00021.
    >> Share

  85. VLACHAKIS PK, Varlamos C, Benetou DR, Kanakakis I, et al
    Periprocedural Antithrombotic Treatment in Complex Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2022;79:407-419.
    >> Share

  86. DENG X, Liu Y, Xu Z, Wang Z, et al
    lncRNA Nuclear Factor of Activated T Cells Knockdown Alleviates Hypoxia/Reoxygenation-induced Cardiomyocyte Apoptosis by Upregulating HIF-1alpha Expression.
    J Cardiovasc Pharmacol. 2022;79:479-488.
    >> Share

    March 2022
  87. BROMAGE DI, Pareek N, Cannata A, Ameri P, et al
    Targeting inflammation after myocardial infarction - another piece of the puzzle.
    J Cardiovasc Pharmacol. 2022 Mar 15. pii: 00005344-990000000-00009.
    >> Share

  88. ZHOU S, Liu P, Zhang G, Cheng Z, et al
    HDAC1 depletion alleviates coronary heart disease via the microRNA-182-mediated TGF-beta/Smad signaling pathway.
    J Cardiovasc Pharmacol. 2022 Mar 11. pii: 00005344-990000000-00008.
    >> Share

  89. HU MJ, Tan JS, Gao XJ, Yang JG, et al
    De-Escalation of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: An Updated Meta-Analysis and Trial Sequential Analysis of 21 studies and 38741 patients.
    J Cardiovasc Pharmacol. 2022 Mar 4. pii: 00005344-990000000-00029.
    >> Share

  90. POLETTO BONETTO JH, Luz de Castro A, Fernandes RO, Corssac GB, et al
    Sulforaphane Effects on Cardiac Function and Calcium-Handling-Related Proteins in 2 Experimental Models of Heart Disease: Ischemia-Reperfusion and Infarction.
    J Cardiovasc Pharmacol. 2022;79:325-334.
    >> Share

    February 2022
  91. BERGH N, Myredal A, Nivedahl P, Petzold M, et al
    Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome - a systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Feb 14. pii: 00005344-900000000-98046.
    >> Share

  92. XU H, Tilley DG
    Pepducin-mediated GPCR signaling in the cardiovascular system.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98051.
    >> Share

  93. DEL BUONO MG, Damonte JI, Chiabrando JG, Markley R, et al
    Effect of IL-1 Blockade with Anakinra on Heart Failure Outcomes in Patients with Anterior versus Non-Anterior STEMI.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98049.
    >> Share

  94. BEAVERS CJ, Effoe SA, Dobesh PP
    Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor.
    J Cardiovasc Pharmacol. 2022;79:161-167.
    >> Share

    January 2022
  95. MA Y, Zhong PY, Shang YS, Bai N, et al
    Comparison of ticagrelor with clopidogrel in East Asian patients with acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials.
    J Cardiovasc Pharmacol. 2022 Jan 27. pii: 00005344-900000000-98056.
    >> Share

  96. CIZMAROVA B, Evinova A, Racay P, Birkova A, et al
    The effect of oestrogen supplementation on antioxidant enzymes and mitochondrial respiratory function after myocardial infarction of ovariectomized rats.
    J Cardiovasc Pharmacol. 2022 Jan 21. pii: 00005344-900000000-98057.
    >> Share

  97. KIM Y, Byun S, Kim HY, Kim DB, et al
    Long-term beta-blocker therapy after myocardial infarction without heart failure in the reperfusion era - systemic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98062.
    >> Share

  98. ZOU HT, Yang GH, Cai YJ, Chen H, et al
    Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98061.
    >> Share

  99. AL-ANI MA, Murray MR, Taha MB, Meece L, et al
    Impact of Laparoscopic Sleeve Gastrectomy on Cardiovascular Pharmacotherapy in Left Ventricular Assist Device Patients.
    J Cardiovasc Pharmacol. 2022 Jan 17. pii: 00005344-900000000-98060.
    >> Share

    December 2021
  100. WANG K, Tang R, Wang S, Xiong Y, et al
    Isoform-selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Protection through the HDACs/CREB/PGC-1alpha Signaling Pathway.
    J Cardiovasc Pharmacol. 2021 Dec 28. pii: 00005344-900000000-98074.
    >> Share

  101. LIU X, Qi K, Gong Y, Long X, et al
    Ferulic Acid Alleviates Myocardial Ischemia Reperfusion Injury Via Upregulating AMPKalpha2 Expression-Mediated Ferroptosis Depression.
    J Cardiovasc Pharmacol. 2021;79:489-500.
    >> Share

  102. SHRESTHA DB, Budhathoki P, Sedhai YR, Khadka M, et al
    Colchicine for patients with coronary artery disease: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98085.
    >> Share

  103. BRAGA CL, Acquarone M, da C Arona V, Osorio BS, et al
    Can epigenetics help solve the puzzle between concomitant cardiovascular injury and severity of COVID-19?
    J Cardiovasc Pharmacol. 2021 Dec 10. pii: 00005344-900000000-98080.
    >> Share

  104. GODO S, Takahashi J, Yasuda S, Shimokawa H, et al
    Endothelium in Coronary Macrovascular and Microvascular Diseases.
    J Cardiovasc Pharmacol. 2021;78.
    >> Share

  105. SAYED-PATHAN NI, Kumar P, Paknikar KM, Gajbhiye V, et al
    MicroRNAs: A Neoteric Approach to Understand Pathogenesis, Diagnose, and Treat Myocardial Infarction.
    J Cardiovasc Pharmacol. 2021;78:773-781.
    >> Share

  106. YANG J, Xiang Z, Zhang J, Yang J, et al
    miR-24 Alleviates MI/RI by Blocking the S100A8/TLR4/MyD88/NF-kB Pathway.
    J Cardiovasc Pharmacol. 2021;78:847-857.
    >> Share

    November 2021
  107. MA Y, Zhong PY, Shang YS, Bai N, et al
    Efficacy and Safety of Short-Term Dual Antiplatelet Therapy in East Asians: A Systematic Review and a Meta-Analysis of Randomized Clinical Trials.
    J Cardiovasc Pharmacol. 2021;79:264-272.
    >> Share

  108. TEMIZ-RESITOGLU M, Guden DS, Senol SP, Vezir O, et al
    Pharmacological inhibition of mTOR attenuates DOCA-salt-induced hypertension and related pathophysiology: regulation of oxidative stress, inflammation and cardiovascular hypertrophy in male rats.
    J Cardiovasc Pharmacol. 2021 Nov 23. pii: 00005344-900000000-98105.
    >> Share

  109. WINGLER LM, Feld AP
    Nanobodies as probes and modulators of cardiovascular GPCRs.
    J Cardiovasc Pharmacol. 2021 Nov 19. pii: 00005344-900000000-98107.
    >> Share

  110. HIJAZI Y, Karkabi B, Feldman M, Malca B, et al
    Bridging care transition after hospitalization for atrial fibrillation and coronary interventions.
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98113.
    >> Share

  111. GRAGNANO F, Calabro P, Cattano D
    CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach?
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98112.
    >> Share

  112. CATURANO A, Spiezia S, Sasso FC
    Statin effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Haemodialysis.
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98118.
    >> Share

  113. LI X, Dang Y
    Inhibition of GARS1-DT Protects Against Hypoxic Injury in H9C2 Cardiomyocytes via Sponging miR-212-5p.
    J Cardiovasc Pharmacol. 2021;78:e714-e721.
    >> Share

    October 2021
  114. ZHANG Y, Zhao X, Ye Y, Li Q, et al
    Clinical Outcomes after Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms.
    J Cardiovasc Pharmacol. 2021 Oct 26. pii: 00005344-900000000-98125.
    >> Share

  115. MELITA H, Manolis AA, Manolis TA, Manolis AS, et al
    Lipoprotein (a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk.
    J Cardiovasc Pharmacol. 2021 Oct 20. pii: 00005344-900000000-98128.
    >> Share

  116. HORIKOSHI T, Nakamura T, Yoshizaki T, Nakamura J, et al
    Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis.
    J Cardiovasc Pharmacol. 2021 Oct 6. pii: 00005344-900000000-98138.
    >> Share

  117. ASSMANN AK, Goschmer D, Sugimura Y, Chekhoeva A, et al
    A role for peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists in counteracting the degeneration of cardiovascular grafts.
    J Cardiovasc Pharmacol. 2021 Oct 4. pii: 00005344-900000000-98134.
    >> Share

  118. WANG X, Sun Q, Hu W
    Carvedilol Protects Against the H2O2-induced Cell Damages in Rat Myoblasts by Regulating the Circ_NFIX/miR-125b-5p/TLR4 Signal Axis.
    J Cardiovasc Pharmacol. 2021;78:604-614.
    >> Share

    September 2021
  119. DU X, Ma Z, Li L, Zhong X, et al
    Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.
    J Cardiovasc Pharmacol. 2021;78:e675-e680.
    >> Share

  120. LOPEZ AE, Bauza MDR, Cuniberti L, Crottogini AJ, et al
    Gene Therapy: Targeting Cardiomyocyte Proliferation to Repopulate the Ischemic Heart.
    J Cardiovasc Pharmacol. 2021;78:346-360.
    >> Share

  121. ZHANG DM, Chen SL
    Potential Mechanisms of In-stent Neointimal Atherosclerotic Plaque Formation.
    J Cardiovasc Pharmacol. 2021;78:388-393.
    >> Share

    August 2021
  122. DIAZ-CANESTRO C, Xu A
    The impact of different adipose depots on cardiovascular disease.
    J Cardiovasc Pharmacol. 2021 Aug 19. pii: 00005344-900000000-98098.
    >> Share

  123. LIU XW, Lu MK, Zhong HT, Liu JJ, et al
    Panax Notoginseng Saponins Protect H9c2 Cells From Hypoxia-reoxygenation Injury Through the Forkhead Box O3a Hypoxia-inducible Factor-1 Alpha Cell Signaling Pathway.
    J Cardiovasc Pharmacol. 2021;78:e681-e689.
    >> Share

  124. JI P, Song X, Lv Z
    Knockdown of circ_0004104 Alleviates Oxidized Low-Density Lipoprotein-Induced Vascular Endothelial Cell Injury by Regulating miR-100/TNFAIP8 Axis.
    J Cardiovasc Pharmacol. 2021;78:269-279.
    >> Share

  125. YUAN M, Wu B, Zhang L, Wang H, et al
    CD40L/CD40 Regulates Adipokines and Cytokines by H3K4me3 Modification in Epicardial Adipocytes.
    J Cardiovasc Pharmacol. 2021;78:228-234.
    >> Share

    July 2021
  126. DEL BUONO MG, Damonte JI, Trankle CR, Bhardwaj H, et al
    Sacubitril/Valsartan for the prevention and treatment post-infarction heart failure: ready to use?
    J Cardiovasc Pharmacol. 2021 Jul 2. pii: 00005344-900000000-98179.
    >> Share

  127. SOLTAN F, Esmaili Dahej M, Yadegari M, Moradi A, et al
    Resveratrol Confers Protection Against Ischemia/Reperfusion Injury by Increase of Angiotensin (1-7) Expression in a Rat Model of Myocardial Hypertrophy.
    J Cardiovasc Pharmacol. 2021;78:e55-e64.
    >> Share

  128. YIN CL, Liu X, Wang HX, Yan MC, et al
    Dynamic Changes in Plasma Urotensin II and Its Correlation With Plaque Stability.
    J Cardiovasc Pharmacol. 2021;78:e147-e155.
    >> Share

  129. CAI X, Li B, Wang Y, Zhu H, et al
    CircJARID2 Regulates Hypoxia-Induced Injury in H9c2 Cells by Affecting miR-9-5p-Mediated BNIP3.
    J Cardiovasc Pharmacol. 2021;78:e77-e85.
    >> Share

  130. CARBONE A, Bottino R, Russo V, D'Andrea A, et al
    Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports.
    J Cardiovasc Pharmacol. 2021;78:e20-e29.
    >> Share

    June 2021
  131. PASCALE JV, Lucchesi PA, Garcia V
    Unraveling the Role of 12- and 20- HETE in Cardiac Pathophysiology: G-Protein-Coupled Receptors, Pharmacological Inhibitors, and Transgenic Approaches.
    J Cardiovasc Pharmacol. 2021;77:707-717.
    >> Share

  132. ZHANG Y, Nie H, Li S, Deng Y, et al
    Carbon Monoxide-Saturated Polymerized Placenta Hemoglobin Optimizes Mitochondrial Function and Protects Heart Against Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2021;77:814-821.
    >> Share

  133. YE G, Wang S, Peng D
    Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021;77:787-795.
    >> Share

    May 2021
  134. NANDKEOLYAR S, Ryu R, Mohammed A, Cordero-Caban K, et al
    A Review of Inotropes and Inopressors for Effective Utilization in Patients with Acute Decompensated Heart Failure.
    J Cardiovasc Pharmacol. 2021 May 28. pii: 00005344-900000000-98208.
    >> Share

  135. MA B, Zhao M, Guo Z
    Circular RNA circ_0010729 Knockdown Attenuates Oxygen-Glucose Deprivation-Induced Human Cardiac Myocytes Injury by miR-338-3p/CALM2 Axis.
    J Cardiovasc Pharmacol. 2021;77:594-602.
    >> Share

  136. LIU S, Liao Q, Xu W, Zhang Z, et al
    MiR-129-5p Protects H9c2 Cardiac Myoblasts From Hypoxia/Reoxygenation Injury by Targeting TRPM7 and Inhibiting NLRP3 Inflammasome Activation.
    J Cardiovasc Pharmacol. 2021;77:586-593.
    >> Share

    April 2021
  137. LEE CC, Chen WT, Chen SY, Lee TM, et al
    Taurine Alleviates Sympathetic Innervation by Inhibiting NLRP3 Inflammasome in Postinfarcted Rats.
    J Cardiovasc Pharmacol. 2021;77:745-755.
    >> Share

  138. TESTA A, Frati G, Versaci F, Biondi-Zoccai G, et al
    Ischemia-Reperfusion Injury: Can We Stop the Curing-Hurting Paradox?
    J Cardiovasc Pharmacol. 2021;77:427-429.
    >> Share

  139. SIMARD T, Motazedian P, Dhaliwal S, Di Santo P, et al
    Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2021;77:450-457.
    >> Share

  140. DE BIASE D, Biondi-Zoccai G, Versaci F, Frati G, et al
    Management of Chronic Stable Angina: Modern Microbiomedical Research Provides Insights Into Traditional Chinese Medicine Treatments.
    J Cardiovasc Pharmacol. 2021;77:421-423.
    >> Share

    March 2021
  141. SCHAUER A, Barthel P, Adams V, Linke A, et al
    Pharmacological Pre- and Postconditioning With Levosimendan Protect H9c2 Cardiomyoblasts From Anoxia/Reoxygenation-induced Cell Death via PI3K/Akt Signaling.
    J Cardiovasc Pharmacol. 2021;77:378-385.
    >> Share

  142. WANG H, Pang W, Xu X, You B, et al
    Cryptotanshinone Attenuates Ischemia/Reperfusion-induced Apoptosis in Myocardium by Upregulating MAPK3.
    J Cardiovasc Pharmacol. 2021;77:370-377.
    >> Share

  143. AIMO A, Egea OI, Emdin M, Bayes-Genis A, et al
    Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury.
    J Cardiovasc Pharmacol. 2021;77:332-333.
    >> Share

    February 2021
  144. ZHAO X, Chen Y, Li L, Zhai J, et al
    Effect of DLT-SML on Chronic Stable Angina Through Ameliorating Inflammation, Correcting Dyslipidemia, and Regulating Gut Microbiota.
    J Cardiovasc Pharmacol. 2021;77:458-469.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016